First Line Therapy for Patients With Metastatic Breast Cancer
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 123
- Registration Number
- NCT00456846
- Locations
- ๐จ๐ฆ
BC Cancer Agency-Burnaby, Burnaby, British Columbia, Canada
๐จ๐ฆMount Sinai Hospital, Toronto, Ontario, Canada
๐จ๐ฆThe Royal Victoria Hospital, Barrie, Ontario, Canada
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 499
- Registration Number
- NCT00452569
- Locations
- ๐ต๐ฑ
Klinika Hematologii Nowotworow Krwi i Transplantacji - Szpiku Akademii Medycznej, Wroclaw, Poland
๐ฎ๐ณDepartment of Medical Oncology/Regional Cancer Centre, Trivandrum, India
๐ฎ๐ณDepartment of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, India
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
- Conditions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 90
- Registration Number
- NCT00446433
- Locations
- ๐บ๐ธ
Advanced Clinical Therapeutics, Tucson, Arizona, United States
๐บ๐ธWashington Hospital Center Physicians Office Building, Washington, District of Columbia, United States
๐บ๐ธAdvanced Clinical Research Institute, Anaheim, California, United States
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 131
- Registration Number
- NCT00426764
- Locations
- ๐บ๐ธ
Hematology Oncology Assoc. of IL Orchard Research LLC, Chicago, Illinois, United States
๐ฉ๐ชCharite Universitatsmedizin Berlin campus Virchow Klinikum Centrum fur Tumormedizin, Berlin, Germany
๐ช๐ธHospital Universitario Vall D Hebron, Barcelona, Spain
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 351
- Registration Number
- NCT00424047
- Locations
- ๐ฎ๐ช
University Hospital GalwayHaematology Department, Galway, Co. Galway, Ireland
๐จ๐ญCentre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
๐ต๐ฑInstitute of Haematology and Blood Transfusion, Warsaw, Poland
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 587
- Registration Number
- NCT00420849
- Locations
- ๐ฆ๐น
Wilhelminenspital, Vienna, Montlearstrasse 37, Austria
๐ฎ๐ชSt James's Hospital, Dublin, Ireland
๐ช๐ธH. Clรญnico de Salamanca, Salamanca, Spain
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 52
- Registration Number
- NCT00419250
- Locations
- ๐บ๐ธ
University of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธIndiana University Medical center, Indianapolis, Indiana, United States
๐บ๐ธThe Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 217
- Registration Number
- NCT00413036
- Locations
- ๐บ๐ธ
Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States
๐บ๐ธPalm Beach Cancer Institute, West Palm Beach, Florida, United States
๐บ๐ธAccess Clinical Research, Rancho Mirage, California, United States
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
- Conditions
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT00407407
- Locations
- ๐บ๐ธ
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 459
- Registration Number
- NCT00405756
- Locations
- ๐ฆ๐น
University Hospital Innsbruck, Innsbruck, Austria
๐ง๐พRepublican Scientific and Practical Centre of Radiation Medicine and Human Ecology, Gomel, Belarus
๐ง๐ชAZ St-Jan Brugge Oostende AV, Brugge, Belgium